
Opinion|Videos|March 27, 2025
Monitoring Strategies for Managing ADC Toxicities in mBC
Panelists discuss how pharmacists should monitor neutropenia, diarrhea, and mucositis from sacituzumab govitecan (SG); interstitial lung disease (ILD) and neutropenia from trastuzumab deruxtecan (T-DXd); and neutropenia and ILD from datopotamab deruxtecan (Dato-DXd). Proactive management is essential for patient safety.
Advertisement
Episodes in this series

Video content above has been prompted by the following:
- Toxicity management is critical for patients on antibody-drug conjugates (ADCs). What are the most important ADC-related AEs that pharmacists should monitor (eg, neutropenia, diarrhea, ILD, mucositis) for T-DXd, SG, and Dato-DXd?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Grants Priority Review to Finerenone for Chronic Kidney Disease in Adults With Type 1 Diabetes
2
Expanding the Field: Who Now Qualifies for CGM, AID, and Continuous Ketone Monitoring?
3
Depression Common in Asthma, But Moderate to Severe Disease Worsens Outcomes
4
Can GLP-1 Receptor Agonists Improve Outcomes in Patients at Risk for Endometrial Cancer?
5







































































































































